A phase II, single-arm study evaluating the role of rucaparib as the maintenance therapy for advanced pancreatic cancer with the germline or somatic mutations in BRCA1, BRCA2, or PALB2 enrolled 46 patients, 42 of whom were eligible for the evaluation. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.